Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.

MLA

Takayoshi, Kotoe, et al. “Suggestion of Added Value by Bevacizumab to Chemotherapy in Patients with Unresectable or Recurrent Small Bowel Cancer.” Cancer Chemotherapy and Pharmacology, vol. 80, no. 2, Aug. 2017, pp. 333–42. EBSCOhost, https://doi.org/10.1007/s00280-017-3371-0.

APA

Takayoshi, K., Kusaba, H., Uenomachi, M., Mitsugi, K., Makiyama, C., Makiyama, A., Uchino, K., Shirakawa, T., Shibata, Y., Shinohara, Y., Inadomi, K., Tsuchihashi, K., Arita, S., Ariyama, H., Esaki, T., Akashi, K., & Baba, E. (2017). Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemotherapy and Pharmacology, 80(2), 333–342. https://doi.org/10.1007/s00280-017-3371-0

Chicago

Takayoshi, Kotoe, Hitoshi Kusaba, Masato Uenomachi, Kenji Mitsugi, Chinatsu Makiyama, Akitaka Makiyama, Keita Uchino, et al. 2017. “Suggestion of Added Value by Bevacizumab to Chemotherapy in Patients with Unresectable or Recurrent Small Bowel Cancer.” Cancer Chemotherapy and Pharmacology 80 (2): 333–42. doi:10.1007/s00280-017-3371-0.